Pregabalin capsule placebo

Phase 2

SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Pregabalin capsule placebo is one of 2 therapeutic programs targeting Post Herpetic Neuralgia (PHN). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Post Herpetic Neuralgia (PHN)Recruiting

Post Herpetic Neuralgia (PHN)Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Post Herpetic Neuralgia (PHN)

#DrugCompanyPhaseTrials

HL-1186

SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Phase 2

1 2

Pregabalin capsule placebo

SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Post Herpetic Neuralgia (PHN)

NCT07758920

Clinical

Trials by Indication[1]

Post Herpetic Neuralgia (PHN)1 trial

A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia

Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07758920·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pregabalin capsule placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pregabalin capsule placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Pregabalin capsule placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Post Herpetic Neuralgia (PHN)1 trial

References

Drug Info

Quick Facts

Related News